GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » JCR Pharmaceuticals Co Ltd (TSE:4552) » Definitions » Cyclically Adjusted Revenue per Share

JCR Pharmaceuticals Co (TSE:4552) Cyclically Adjusted Revenue per Share : 円232.52 (As of Dec. 2023)


View and export this data going back to 2011. Start your Free Trial

What is JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share?

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

JCR Pharmaceuticals Co's adjusted revenue per share for the three months ended in Dec. 2023 was 円75.355. Add all the adjusted revenue per share for the past 10 years together and divide the count will get our Cyclically Adjusted Revenue per Share, which is 円232.52 for the trailing ten years ended in Dec. 2023.

During the past 12 months, JCR Pharmaceuticals Co's average Cyclically Adjusted Revenue Growth Rate was -100.00% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the Cyclically Adjusted Revenue Growth Rate using Cyclically Adjusted Revenue per Share data.

During the past 13 years, the highest 3-Year average Cyclically Adjusted Revenue Growth Rate of JCR Pharmaceuticals Co was 13.40% per year. The lowest was 6.40% per year. And the median was 11.30% per year.

As of today (2024-06-06), JCR Pharmaceuticals Co's current stock price is 円567.00. JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share for the quarter that ended in Dec. 2023 was 円232.52. JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is 2.44.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of JCR Pharmaceuticals Co was 24.79. The lowest was 2.42. And the median was 11.54.


JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Historical Data

The historical data trend for JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Chart

JCR Pharmaceuticals Co Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
Cyclically Adjusted Revenue per Share
Get a 7-Day Free Trial Premium Member Only Premium Member Only 144.45 156.35 189.08 210.80 -

JCR Pharmaceuticals Co Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Cyclically Adjusted Revenue per Share Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 210.80 218.08 227.45 232.52 -

Competitive Comparison of JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share

For the Drug Manufacturers - General subindustry, JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio, along with its competitors' market caps and Cyclically Adjusted PS Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio distribution charts can be found below:

* The bar in red indicates where JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio falls into.



JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Calculation

E10 is a concept invented by Prof. Robert Shiller, who uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Revenue per Share and the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years.

What is Cyclically Adjusted Revenue per Share? How do we calculate Cyclically Adjusted Revenue per Share?

Cyclically Adjusted Revenue per Share is the average of the inflation adjusted Revenue per Share of a company over the past 10 years. Let's use an example to explain.

If we want to calculate the Cyclically Adjusted Revenue per Share of Wal-Mart (WMT) for Dec. 31, 2010, we need to have the inflation data and the revenue per share from 2001 through 2010.

We adjusted the 2001 revenue per share data with the total inflation from 2001 through 2010 to the equivalent revenue in 2010. If the total inflation from 2001 to 2010 is 40%, and Wal-Mart's revenue is $1 a share in 2001, then the 2001's equivalent revenue in 2010 is $1.4 a share. If Wal-Mart's revenue is $1 again in 2002, and the total inflation from 2002 through 2010 is 35%, then the equivalent 2002 revenue in 2010 is $1.35. So on and so forth, you get the equivalent revenue per share of past 10 years. Then you add them together and divided the sum by the count to get Cyclically Adjusted Revenue per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

For example, JCR Pharmaceuticals Co's adjusted Revenue per Share data for the three months ended in Dec. 2023 was:

Adj_RevenuePerShare= Revenue per Share /CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=75.355/106.8000*106.8000
=75.355

Current CPI (Dec. 2023) = 106.8000.

JCR Pharmaceuticals Co Quarterly Data

Revenue per Share CPI Adj_RevenuePerShare
201403 31.721 95.700 35.400
201406 29.776 98.000 32.450
201409 33.913 98.500 36.771
201412 32.477 97.900 35.429
201503 35.403 97.900 38.621
201506 32.361 98.400 35.124
201509 36.109 98.500 39.152
201512 33.284 98.100 36.236
201603 34.211 97.900 37.321
201606 29.836 98.100 32.482
201609 37.224 98.000 40.567
201612 35.966 98.400 39.036
201703 39.227 98.100 42.706
201706 34.578 98.500 37.492
201709 46.000 98.800 49.725
201712 40.870 99.400 43.913
201803 43.155 99.200 46.461
201806 37.897 99.200 40.800
201809 45.095 99.900 48.210
201812 42.366 99.700 45.383
201903 61.570 99.700 65.955
201906 41.666 99.800 44.588
201909 48.990 100.100 52.269
201912 55.143 100.500 58.600
202003 53.957 100.300 57.454
202006 41.745 99.900 44.628
202009 46.525 99.900 49.738
202012 68.226 99.300 73.379
202103 85.884 99.900 91.816
202106 79.042 99.500 84.841
202109 149.505 100.100 159.512
202112 95.667 100.100 102.070
202203 87.052 101.100 91.960
202206 77.382 101.800 81.183
202209 48.015 103.100 49.738
202212 88.526 104.100 90.822
202303 61.109 104.400 62.514
202306 86.262 105.200 87.574
202309 107.327 106.200 107.933
202312 75.355 106.800 75.355

Add all the adjusted revenue per share together and divide 10 will get our Cyclically Adjusted Revenue per Share.


JCR Pharmaceuticals Co  (TSE:4552) Cyclically Adjusted Revenue per Share Explanation

If a company grows much fast than inflation, Cyclically Adjusted Revenue per Share may underestimate the company's revenue. Cyclically Adjusted PS Ratio can seem to be too high even the actual PS Ratio is low.

For the Cyclically Adjusted PS Ratio, the revenue per share of the past 10 years are inflation-adjusted and averaged. The result is used for P/S calculation. Since it looks at the average over the last 10 years, the Cyclically Adjusted PS Ratio is also called CAPS Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PS Ratio. The Cyclically Adjusted Revenue per Share is the average of the inflation adjusted revenue per share of a company over the past 10 years.

JCR Pharmaceuticals Co's Cyclically Adjusted PS Ratio of today is calculated as

Cyclically Adjusted PS Ratio=Share Price/Cyclically Adjusted Revenue per Share
=567.00/232.52
=2.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

During the past 13 years, the highest Cyclically Adjusted PS Ratio of JCR Pharmaceuticals Co was 24.79. The lowest was 2.42. And the median was 11.54.


Be Aware

Cyclically Adjusted PS Ratio works better for cyclical companies. It gives you a better idea on the company's real revenue value.


JCR Pharmaceuticals Co Cyclically Adjusted Revenue per Share Related Terms

Thank you for viewing the detailed overview of JCR Pharmaceuticals Co's Cyclically Adjusted Revenue per Share provided by GuruFocus.com. Please click on the following links to see related term pages.


JCR Pharmaceuticals Co (TSE:4552) Business Description

Traded in Other Exchanges
Address
3-19 Kasuga-cho, Ashiya, Hyogo, JPN, 659-0021
JCR Pharmaceuticals Co Ltd is a major drug manufacturing company proactively engaged in the research of enzymes and proteins. The company maintains a focus toward developing value-added treatment options to address unmet medical needs. JCR utilizes international partnerships as a component of its growth strategy. The vast majority of JCR's revenue is generated from its pharmaceutical operations, followed by medical devices and laboratory equipment. A portion of the company's sales are derived from licensing agreements.

JCR Pharmaceuticals Co (TSE:4552) Headlines

No Headlines